Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).

被引：0

作者：

Yoo, Changhoon

Kim, Kyu-Pyo

Song, Ki Byung

Lee, Sang Soo

Park, Do Hyun

Song, Tae Jun

Lee, Seung Soo

Park, Jin-Hong

Hwang, Dae Wook

Lee, Jae Hoon

Shin, Sang Hyun

Shin, Eunseon

Ryoo, Baek-Yeol

Kim, Song Cheol

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea

[4] Asan Med Ctr, Dept Radiol, Seoul, South Korea

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea

[6] Asan Med Ctr, Dept Oncol, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.342

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

342

引用

页数：2

共 50 条

[21] Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Katz, Matthew H. G.
Shi, Qian
Ahmad, Syed A.
Herman, Joseph M.
Marsh, Robert de W.
Collisson, Eric
Schwartz, Lawrence
Frankel, Wendy
Martin, Robert
Conway, William
Truty, Mark
Kindler, Hedy
Lowy, Andrew M.
Bekaii-Saab, Tanios
Philip, Philip
Talamonti, Mark
Cardin, Dana
LoConte, Noelle
Shen, Perry
Hoffman, John P.
Venook, Alan P.
JAMA SURGERY, 2016, 151 (08)
[22] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma
Lee, Choong-kun
Hwang, Ho Kyoung
Jeung, Hei-Cheul
Chon, Hongjae
Park, Hyung Soon
Kim, Min Hwan
Park, Mi-Suk
Kang, Chang Moo
Choi, Hye Jin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[23] Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC)
Agarwal, Parul
Qi, Hanfei
Munjal, Kabeer
Gai, Jessica
Ferguson, Anna
Parkinson, Rose
Harrison, Jeanne
Rodriguez, Christina
Anders, Robert A.
Thompson, Elizabeth D.
Burkhart, Richard
He, Jin
Narang, Amol
De Jesus-Acosta, Ana
Zheng, Lei
Jaffee, Elizabeth M.
George, Ben
Laheru, Daniel A.
Yarchoan, Mark
Osipov, Arsen
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Tislelizumab combined with gemcitabine and albumin paclitaxel as preoperative therapy for patients with borderline resectable pancreatic cancer: A prospective, single-arm, phase II trial
He, Yonggang Gang
Huang, Xiaobing
Zheng, Lu
Li, Jing
Zhao, Chongyu
Li, Ying
Zuo, Guohua
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
Hong, Theodore S.
Yeap, Beow Y.
Horick, Nora K.
Wo, Jennifer Yon-Li
Weekes, Colin D.
Allen, Jill N.
Qadan, Motaz
Oberstein, Paul Eliezer
Jain, Rakesh K.
Blaszkowsky, Lawrence Scott
Wolpin, Brian M.
Laheru, Daniel A.
Messersmith, Wells A.
Ly, Leilana
Drapek, Lorraine C.
Ting, David Tsai
Burkhart, Richard A.
Fernandez-del Castillo, Carlos
Kimmelman, Alec
Ryan, David P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 719 - 719
[26] Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: A prospective, multi-institutional, phase II trial
Mizuma, Masamichi
Motoi, Fuyuhiko
Ishida, Kazuyuki
Fujishima, Fumiyoshi
Ottomo, Shigeru
Oikawa, Masaya
Okada, Takaho
Shimamura, Hiromune
Takemura, Shinichi
Ono, Fuminori
Akada, Masanori
Nakagawa, Kei
Katayose, Yu
Egawa, Shinichi
Unno, Michiaki
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[27] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
Lee, Choong-kun
Hwang, Ho Kyoung
Jeung, Hei-Cheul
Chon, Hongjae
Park, Hyung Soon
Kim, Min Hwan
Kim, Sung Hyun
Park, Mi-Suk
Kang, Chang Moo
Choi, Hye Jin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 715 - 715
[28] Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer.
Kwon, J. H.
Chie, E. K.
Kim, J. H.
Im, S.
Oh, D.
Kim, Y.
Han, S.
Lee, K.
Jang, J.
Kim, T.
Kim, J. S.
Han, H. S.
Kim, S.
Yoon, Y. B.
Bang, Y.
Ha, S. W.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29] A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Keiichi Okano
Hironobu Suto
Minoru Oshima
Eri Maeda
Naoki Yamamoto
Keitaro Kakinoki
Hideki Kamada
Tsutomu Masaki
Shigeo Takahashi
Toru Shibata
Yasuyuki Suzuki
Annals of Surgical Oncology, 2017, 24 : 2777 - 2784
[30] A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Okano, Keiichi
Suto, Hironobu
Oshima, Minoru
Maeda, Eri
Yamamoto, Naoki
Kakinoki, Keitaro
Kamada, Hideki
Masaki, Tsutomu
Takahashi, Shigeo
Shibata, Toru
Suzuki, Yasuyuki
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (09) : 2777 - 2784

← 1 2 3 4 5 →